Internet of Things (IoT) with deep learning (DL) is drastically growing and plays a significant role in many applications, including medical and healthcare systems. It can help users in this field get an advantage in terms of enhanced touchless authentication, especially in spreading infectious diseases like coronavirus disease 2019 (COVID-19). Even though there is a number of available security systems, they suffer from one or more of issues, such as identity fraud, loss of keys and passwords, or spreading diseases through touch authentication tools. To overcome these issues, IoT-based intelligent control medical authentication systems using DL models are proposed to enhance the security factor of medical and healthcare places effectively. This work applies IoT with DL models to recognize human faces for authentication in smart control medical systems. We use Raspberry Pi (RPi) because it has low cost and acts as the main controller in this system. The installation of a smart control system using general-purpose input/output (GPIO) pins of RPi also enhanced the antitheft for smart locks, and the RPi is connected to smart doors. For user authentication, a camera module is used to capture the face image and compare them with database images for getting access. The proposed approach performs face detection using the Haar cascade techniques, while for face recognition, the system comprises the following steps. The first step is the facial feature extraction step, which is done using the pretrained CNN models (ResNet-50 and VGG-16) along with linear binary pattern histogram (LBPH) algorithm. The second step is the classification step which can be done using a support vector machine (SVM) classifier. Only classified face as genuine leads to unlock the door; otherwise, the door is locked, and the system sends a notification email to the home/medical place with detected face images and stores the detected person name and time information on the SQL database. The comparative study of this work shows that the approach achieved 99.56% accuracy compared with some different related methods.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858039 | PMC |
http://dx.doi.org/10.1155/2022/5137513 | DOI Listing |
Alzheimers Dement
December 2024
Columbia University Irving Medical Center, New York, NY, USA.
Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China;, Beijing, China.
Background: Individuals with type 2 diabetes mellitus (T2DM) face an increased risk of dementia. Recent discoveries indicate that SGLT2 inhibitors, a newer class of anti-diabetic medication, exhibit beneficial metabolic effects beyond glucose control, offering a potential avenue for mitigating the risk of Alzheimer's disease (AD). However, limited evidence exists regarding whether the use of SGLT2 inhibitors effectively reduces the risk of AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFBackground: Genetic studies have established that loss of function SORL1 gene variants are associated with Alzheimer's disease (AD). SORL1 encodes an endosomal trafficking receptor, SORLA, which regulates endosomal protein recycling through its interaction with the retromer core complex (consisting of VPS26, VPS35 and VPS29). Deficits in the levels and function of the SORLA-retromer complex are thought to underlie AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!